Regeneron Pharma Drug Patent Portfolio
Regeneron Pharma owns 1 purple book drug protected by 72 US patents Given below is the list of Regeneron Pharma's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11525833 | Hydrophobic interaction chromatography-coupled native mass spectrometry for antibody analysis | 29 Nov, 2040 | Active |
| US11053280 | Anti-VEGF protein compositions and methods for producing the same | 18 Aug, 2040 | Active |
| US11104715 | Methods for producing aflibercept in chemically defined media having reduced aflibercept variants | 18 Aug, 2040 | Active |
| US11174283 | Anti-VEGF protein compositions and methods for producing the same | 18 Aug, 2040 | Active |
| US11186625 | Anti-VEGF protein compositions and methods for producing the same | 18 Aug, 2040 | Active |
| US11299532 | Anti-VEGF protein compositions and methods for producing the same | 18 Aug, 2040 | Active |
| US11306135 | Anti-VEGF protein compositions and methods for producing the same | 18 Aug, 2040 | Active |
| US11459373 | Anti-VEGF protein compositions and methods for producing the same | 18 Aug, 2040 | Active |
| US11459374 | Anti-VEGF protein compositions and methods for producing the same | 18 Aug, 2040 | Active |
| US11472861 | Methods for producing aflibercept in chemically defined media having reduced aflibercept variants | 18 Aug, 2040 | Active |
| US11485770 | Anti-VEGF protein compositions and methods for producing the same | 18 Aug, 2040 | Active |
| US11505593 | Anti-VEGF protein compositions and methods for producing the same | 18 Aug, 2040 | Active |
| US11535663 | Methods for producing aflibercept in chemically defined media having reduced aflibercept variants | 18 Aug, 2040 | Active |
| US11542317 | Anti-VEGF protein compositions and methods for producing the same | 18 Aug, 2040 | Active |
| US11548932 | Anti-VEGF protein compositions and methods for producing the same | 18 Aug, 2040 | Active |
| US11732025 | Anti-VEGF protein compositions and methods for producing the same | 18 Aug, 2040 | Active |
| US11753459 | Anti-VEGF protein compositions and methods for producing the same | 18 Aug, 2040 | Active |
| US11793926 | Medical device packaging and related methods | 29 Jul, 2040 | Active |
| US11478588 | Needle shield grip devices and related methods | 25 Jul, 2040 | Active |
| US11439758 | Devices and methods for precision dose delivery | 04 Jun, 2040 | Active |
| US11555176 | Cell culture medium for eukaryotic cells | 27 Jan, 2040 | Active |
| US11850407 | Needle shield grip devices and related methods | 18 Sep, 2039 | Active |
| US11160918 | Medical device packaging and related methods | 29 Jul, 2039 | Active |
| US10973879 | Use of a VEGF antagonist to treat angiogenic eye disorders | 17 May, 2039 | Active |
| US11103552 | High concentration VEGF receptor fusion protein containing formulations | 15 May, 2039 | Active |
| US11433186 | Devices and methods for precision dose delivery | 12 Dec, 2038 | Active |
| US11769597 | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF | 04 Dec, 2038 | Active |
| US11788102 | CHO integration sites and uses thereof | 13 Sep, 2038 | Active |
| US10905786 | Sterilisation method | 06 Mar, 2038 | Active |
| US10918754 | Sterilisation method | 06 Mar, 2038 | Active |
| US11680930 | Methods and systems for chromatography data analysis | 25 Oct, 2037 | Active |
| US11577025 | Devices and methods for overfilling drug containers | 06 Oct, 2037 | Active |
| USD961376 | Packaging | 23 Aug, 2037 | Active |
| USD961377 | Packaging | 23 Aug, 2037 | Active |
| US10182969 | Aseptic piercing system and method | 13 Jul, 2037 | Active |
| US11918785 | Devices and methods for overfilling drug containers | 29 Jun, 2037 | Active |
| US10669594 | Compositions and methods for detecting a biological contaminant | 12 Feb, 2037 | Active |
| US11549154 | Compositions and methods for detecting a biological contaminant | 25 Dec, 2036 | Active |
| USD934069 | Packaging | 26 Oct, 2036 | Active |
| US10927342 | Taurine supplemented cell culture medium and methods of use | 03 Aug, 2036 | Active |
| US11312936 | Taurine supplemented cell culture medium and methods of use | 03 Aug, 2036 | Active |
| USD906102 | Packaging | 29 Dec, 2035 | Active |
| US11268109 | CHO integration sites and uses thereof | 21 Oct, 2035 | Active |
| US9816110 | CHO integration sites and uses thereof | 21 Oct, 2035 | Active |
| US9315281 | System and methods for use in dispensing biopharmaceutical materials | 16 Sep, 2034 | Active |
| USD858754 | Syringe cap | 03 Sep, 2034 | Active |
| US11332771 | Serum-free cell culture medium | 14 Mar, 2034 | Active |
| US11970724 | Serum-free cell culture medium | 14 Mar, 2034 | Active |
| US11707506 | Use of a VEGF antagonist to treat angiogenic eye disorders | 03 Jun, 2032 | Active |
| US9254338 | Use of a VEGF antagonist to treat angiogenic eye disorders | 22 May, 2032 | Active |
| US10130681 | Use of a VEGF antagonist to treat angiogenic eye disorders | 11 Jan, 2032 | Active |
| US10828345 | Use of a VEGF antagonist to treat angiogenic eye disorders | 11 Jan, 2032 | Active |
| US10857205 | Use of a VEGF antagonist to treat angiogenic eye disorders | 11 Jan, 2032 | Active |
| US10888601 | Use of a VEGF antagonist to treat angiogenic eye disorders | 11 Jan, 2032 | Active |
| US11253572 | Use of a VEGF antagonist to treat angiogenic eye disorders | 11 Jan, 2032 | Active |
| US11559564 | Use of a VEGF antagonist to treat angiogenic eye disorders | 11 Jan, 2032 | Active |
| US11975045 | Use of a VEGF antagonist to treat angiogenic eye disorders | 11 Jan, 2032 | Active |
| US11986511 | Use of a VEGF antagonist to treat angiogenic eye disorders | 11 Jan, 2032 | Active |
| US9669069 | Use of a VEGF antagonist to treat angiogenic eye disorders | 11 Jan, 2032 | Active |
| US7771997 | Enhanced expression and stability regions | 02 Jul, 2028 | Active |
| US10415055 | Enhanced expression and stability regions | 04 Jun, 2028 | Active |
| US9222106 | Enhanced expression and stability regions | 04 Jun, 2028 | Active |
| US9562238 | Enhanced expression and stability regions | 04 Jun, 2028 | Active |
| US9932605 | Enhanced expression and stability regions | 04 Jun, 2028 | Active |
| US10464992 | VEGF antagonist formulations suitable for intravitreal administration | 14 Jun, 2027 | Active |
| US11066458 | VEGF antagonist formulations suitable for intravitreal administration | 14 Jun, 2027 | Active |
| US11084865 | VEGF antagonist formulations suitable for intravitreal administration | 14 Jun, 2027 | Active |
| US11732024 | VEGF antagonist formulations suitable for intravitreal administration | 14 Jun, 2027 | Active |
| US10406226 | Method of manufacturing VEGF antagonist fusion proteins | 22 Mar, 2026 | Active |
| USD1035436 | Packaging | 16 Jul, 2024 | Active |
| US7070959 | Modified chimeric polypeptides with improved pharmacokinetic properties | 16 Jun, 2023 | Active |
| US10857231 | Formulations of VEG antagonist fusion proteins and method of manufacturing them | NA | Active |
Regeneron Pharma's Family Patents
Regeneron Pharma Drug List
Given below is the complete list of Regeneron Pharma's drugs and the patents protecting them.
1. Eylea
Eylea is protected by 72 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11525833 | Hydrophobic interaction chromatography-coupled native mass spectrometry for antibody analysis |
29 Nov, 2040
(14 years from now)
| Active |
| US11053280 | Anti-VEGF protein compositions and methods for producing the same |
18 Aug, 2040
(14 years from now)
| Active |
| US11104715 | Methods for producing aflibercept in chemically defined media having reduced aflibercept variants |
18 Aug, 2040
(14 years from now)
| Active |
| US11174283 | Anti-VEGF protein compositions and methods for producing the same |
18 Aug, 2040
(14 years from now)
| Active |
| US11186625 | Anti-VEGF protein compositions and methods for producing the same |
18 Aug, 2040
(14 years from now)
| Active |
| US11299532 | Anti-VEGF protein compositions and methods for producing the same |
18 Aug, 2040
(14 years from now)
| Active |
| US11306135 | Anti-VEGF protein compositions and methods for producing the same |
18 Aug, 2040
(14 years from now)
| Active |
| US11459373 | Anti-VEGF protein compositions and methods for producing the same |
18 Aug, 2040
(14 years from now)
| Active |
| US11459374 | Anti-VEGF protein compositions and methods for producing the same |
18 Aug, 2040
(14 years from now)
| Active |
| US11472861 | Methods for producing aflibercept in chemically defined media having reduced aflibercept variants |
18 Aug, 2040
(14 years from now)
| Active |
| US11485770 | Anti-VEGF protein compositions and methods for producing the same |
18 Aug, 2040
(14 years from now)
| Active |
| US11505593 | Anti-VEGF protein compositions and methods for producing the same |
18 Aug, 2040
(14 years from now)
| Active |
| US11535663 | Methods for producing aflibercept in chemically defined media having reduced aflibercept variants |
18 Aug, 2040
(14 years from now)
| Active |
| US11542317 | Anti-VEGF protein compositions and methods for producing the same |
18 Aug, 2040
(14 years from now)
| Active |
| US11548932 | Anti-VEGF protein compositions and methods for producing the same |
18 Aug, 2040
(14 years from now)
| Active |
| US11732025 | Anti-VEGF protein compositions and methods for producing the same |
18 Aug, 2040
(14 years from now)
| Active |
| US11753459 | Anti-VEGF protein compositions and methods for producing the same |
18 Aug, 2040
(14 years from now)
| Active |
| US11793926 | Medical device packaging and related methods |
29 Jul, 2040
(14 years from now)
| Active |
| US11478588 | Needle shield grip devices and related methods |
25 Jul, 2040
(14 years from now)
| Active |
| US11439758 | Devices and methods for precision dose delivery |
04 Jun, 2040
(14 years from now)
| Active |
| US11555176 | Cell culture medium for eukaryotic cells |
27 Jan, 2040
(14 years from now)
| Active |
| US11850407 | Needle shield grip devices and related methods |
18 Sep, 2039
(13 years from now)
| Active |
| US11160918 | Medical device packaging and related methods |
29 Jul, 2039
(13 years from now)
| Active |
| US10973879 | Use of a VEGF antagonist to treat angiogenic eye disorders |
17 May, 2039
(13 years from now)
| Active |
| US11103552 | High concentration VEGF receptor fusion protein containing formulations |
15 May, 2039
(13 years from now)
| Active |
| US11433186 | Devices and methods for precision dose delivery |
12 Dec, 2038
(12 years from now)
| Active |
| US11769597 | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF |
04 Dec, 2038
(12 years from now)
| Active |
| US11788102 | CHO integration sites and uses thereof |
13 Sep, 2038
(12 years from now)
| Active |
| US10905786 | Sterilisation method |
06 Mar, 2038
(12 years from now)
| Active |
| US10918754 | Sterilisation method |
06 Mar, 2038
(12 years from now)
| Active |
| US11680930 | Methods and systems for chromatography data analysis |
25 Oct, 2037
(11 years from now)
| Active |
| US11577025 | Devices and methods for overfilling drug containers |
06 Oct, 2037
(11 years from now)
| Active |
| USD961376 | Packaging |
23 Aug, 2037
(11 years from now)
| Active |
| USD961377 | Packaging |
23 Aug, 2037
(11 years from now)
| Active |
| US10182969 | Aseptic piercing system and method |
13 Jul, 2037
(11 years from now)
| Active |
| US11918785 | Devices and methods for overfilling drug containers |
29 Jun, 2037
(11 years from now)
| Active |
| US10669594 | Compositions and methods for detecting a biological contaminant |
12 Feb, 2037
(11 years from now)
| Active |
| US11549154 | Compositions and methods for detecting a biological contaminant |
25 Dec, 2036
(10 years from now)
| Active |
| USD934069 | Packaging |
26 Oct, 2036
(10 years from now)
| Active |
| US10927342 | Taurine supplemented cell culture medium and methods of use |
03 Aug, 2036
(10 years from now)
| Active |
| US11312936 | Taurine supplemented cell culture medium and methods of use |
03 Aug, 2036
(10 years from now)
| Active |
| USD906102 | Packaging |
29 Dec, 2035
(9 years from now)
| Active |
| US11268109 | CHO integration sites and uses thereof |
21 Oct, 2035
(9 years from now)
| Active |
| US9816110 | CHO integration sites and uses thereof |
21 Oct, 2035
(9 years from now)
| Active |
| US9315281 | System and methods for use in dispensing biopharmaceutical materials |
16 Sep, 2034
(8 years from now)
| Active |
| USD858754 | Syringe cap |
03 Sep, 2034
(8 years from now)
| Active |
| US11332771 | Serum-free cell culture medium |
14 Mar, 2034
(8 years from now)
| Active |
| US11970724 | Serum-free cell culture medium |
14 Mar, 2034
(8 years from now)
| Active |
| US11707506 | Use of a VEGF antagonist to treat angiogenic eye disorders |
03 Jun, 2032
(6 years from now)
| Active |
| US9254338 | Use of a VEGF antagonist to treat angiogenic eye disorders |
22 May, 2032
(6 years from now)
| Active |
| US10130681 | Use of a VEGF antagonist to treat angiogenic eye disorders |
11 Jan, 2032
(6 years from now)
| Active |
| US10828345 | Use of a VEGF antagonist to treat angiogenic eye disorders |
11 Jan, 2032
(6 years from now)
| Active |
| US10857205 | Use of a VEGF antagonist to treat angiogenic eye disorders |
11 Jan, 2032
(6 years from now)
| Active |
| US10857205 | Use of a VEGF antagonist to treat angiogenic eye disorders |
11 Jan, 2032
(6 years from now)
| Active |
| US10888601 | Use of a VEGF antagonist to treat angiogenic eye disorders |
11 Jan, 2032
(6 years from now)
| Active |
| US11253572 | Use of a VEGF antagonist to treat angiogenic eye disorders |
11 Jan, 2032
(6 years from now)
| Active |
| US11559564 | Use of a VEGF antagonist to treat angiogenic eye disorders |
11 Jan, 2032
(6 years from now)
| Active |
| US11975045 | Use of a VEGF antagonist to treat angiogenic eye disorders |
11 Jan, 2032
(6 years from now)
| Active |
| US11986511 | Use of a VEGF antagonist to treat angiogenic eye disorders |
11 Jan, 2032
(6 years from now)
| Active |
| US9669069 | Use of a VEGF antagonist to treat angiogenic eye disorders |
11 Jan, 2032
(6 years from now)
| Active |
| US7771997 | Enhanced expression and stability regions |
02 Jul, 2028
(2 years from now)
| Active |
| US10415055 | Enhanced expression and stability regions |
04 Jun, 2028
(2 years from now)
| Active |
| US9222106 | Enhanced expression and stability regions |
04 Jun, 2028
(2 years from now)
| Active |
| US9562238 | Enhanced expression and stability regions |
04 Jun, 2028
(2 years from now)
| Active |
| US9932605 | Enhanced expression and stability regions |
04 Jun, 2028
(2 years from now)
| Active |
| US10464992 | VEGF antagonist formulations suitable for intravitreal administration |
14 Jun, 2027
(1 year, 5 months from now)
| Active |
| US11066458 | VEGF antagonist formulations suitable for intravitreal administration |
14 Jun, 2027
(1 year, 5 months from now)
| Active |
| US11084865 | VEGF antagonist formulations suitable for intravitreal administration |
14 Jun, 2027
(1 year, 5 months from now)
| Active |
| US11732024 | VEGF antagonist formulations suitable for intravitreal administration |
14 Jun, 2027
(1 year, 5 months from now)
| Active |
| US10406226 | Method of manufacturing VEGF antagonist fusion proteins |
22 Mar, 2026
(2 months from now)
| Active |
| USD1035436 | Packaging |
16 Jul, 2024
(1 year, 5 months ago)
| Expired |
| US7070959 | Modified chimeric polypeptides with improved pharmacokinetic properties |
16 Jun, 2023
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Eylea's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List